Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Trading Report for (BAX). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Jefferson Research
|
$20.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Baxter International Inc Reaffirms FY 2012 Guidance-Conference Call
Baxter International Inc announced that for fiscal 2012, it expects sales growth in the 4% to 5% range, excluding the impact of foreign currency, and earnings of $4.50 to $4.56 per diluted share. The Company reported revenue of $13.893 billion in fiscal 2011. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $14.192 billion and EPS of $4.53 for fiscal 2012.
Latest Developments for Baxter International Inc
- Baxter International Inc Receives Marketing Authorization For Hyqvia In European Union
- Baxter International Inc Comments On Q2 2013 Revenue Guidance; Issues Q2 2013 EPS Guidance In Line With Analysts' Estimates; Reaffirms FY 2013 Guidance
- Baxter International Inc And Halozyme Therapeutics Inc Announces Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In European Union
- Baxter International Inc Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates-Conference Call
Latest Key Developments in Pharmaceuticals
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb From Warburg Pincus LLC-Reuters
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb-Reuters
- Astec LifeSciences Ltd Recommends Dividend; Announces Appointment Of Statutory Auditors
- J B Chemicals and Pharmaceuticals Ltd Recommends Dividend
- Share this
- Link this
- Digg this
Follow Reuters